SCHEMBL26159062

SCHEMBL26159062

C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(CCCN)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WEE1 P30291 20/20 0.83
PLK1 P53350 3/20 0.83
CRBN Q96SW2 2/20 0.83
GAK O14976 1/20 0.83
EPHB6 O15197 1/20 0.83
JAK2 O60674 1/20 0.83
PRKD3 O94806 1/20 0.83
MAP4K4 O95819 1/20 0.83
PAK4 O96013 1/20 0.83
ABL1 P00519 1/20 0.83
LCK P06239 1/20 0.83
FYN P06241 1/20 0.83
CYP3A4 P08684 1/20 0.83
WEE2 P0C1S8 1/20 0.83
BCR P11274 1/20 0.83
CSNK2A2 P19784 1/20 0.83
SYK P43405 1/20 0.83
CSNK1A1 P48729 1/20 0.83
NEK2 P51955 1/20 0.83
NEK3 P51956 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27164146 0.97 WEE1 (0.81) WEE1PLK1CRBNGAKEPHB6
SCHEMBL29132533 0.94 WEE1 (0.85) WEE1PLK1CRBNGAKEPHB6
SCHEMBL1811019 0.94 WEE1 (0.89) WEE1PLK1CRBNGAKEPHB6
SCHEMBL29132577 0.93 WEE1 (0.83) WEE1PLK1CRBNGAKEPHB6
SCHEMBL27163990 0.93 WEE1 (0.78) WEE1PLK1CRBNGAKEPHB6
SCHEMBL27163951 0.93 WEE1 (0.78) WEE1PLK1CRBNGAKEPHB6
SCHEMBL29132616 0.93 WEE1 (0.82) WEE1PLK1CRBNGAKEPHB6
Hydrochloric Acid SCHEMBL26118325 0.91 WEE1 (0.80) WEE1PLK1CRBNGAKEPHB6
SCHEMBL1813878 0.91 WEE1 (0.86) WEE1PLK1CRBNGAKEPHB6
Adavosertib SCHEMBL30559444 0.91 WEE1 (1.00) WEE1PLK1CRBNGAKEPHB6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240252655-A1 DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS NOVARTIS AG (CH) 2024-08-01 US disclosed
EP-4329815-A1 DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS Novartis AG (CH) 2024-03-06 EP disclosed
US-20230158152-A1 PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME MEDSHINE DISCOVERY INC. (CN) 2023-05-25 US disclosed
US-20230158152-A1 PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME MEDSHINE DISCOVERY INC. (CN) 2023-05-25 US disclosed
WO-2022232634-A1 DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS NOVARTIS AG (CH) 2022-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240252655-A1 DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS USP2, USP1, USP28 WEE1 1990/4885PLK1 376/4885CRBN 182/4885
US-20230158152-A1 PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME PSMA6, PSMC1, PSMA1 WEE1 3948/4885PLK1 2279/4885CRBN 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.